Comparative Pharmacology
Head-to-head clinical analysis: IOMERVU versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOMERVU versus RENOVUE 65.
IOMERVU vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent